Skip to main content
Clinical Trials/DRKS00020132
DRKS00020132
Recruiting
Not Applicable

Explorative study of emerging blood biomarkers in progressive multiple sclerosis - EmBioProMS

Reha- und Universitätsklinikum Ulm0 sites240 target enrollmentDecember 19, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
G35
Sponsor
Reha- und Universitätsklinikum Ulm
Enrollment
240
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 19, 2019
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Reha- und Universitätsklinikum Ulm

Eligibility Criteria

Inclusion Criteria

  • Patients with progressive multiple sclerosis (PMS)
  • \- Duration of the progressive phase of at least 12 months
  • \- Cranial MRI scan within the last three months of baseline\-Visit\*
  • \- EDSS between 1 and 6,5\+
  • \* not obligatory in 50% of the study population (100 patients)
  • \+ a cap of 25% will be applied as the upper limit of patients with EDSS \> 5\.5

Exclusion Criteria

  • \- Patients with relapsing\-remitting multiple sclerosis.
  • \- Acute exacerbation in the last 3 months
  • \- Treatment with\*:
  • Methylprednisolone in the last 30 days
  • Interferon, Glatiramer acetate, Natalizumab, Dimethyl fumarate, Fingolimod and Teriflunomide in the last 3 months
  • Ocrelizumab, Rituximab or Mitoxantrone in the last 12 months
  • With Cladribine or alemtuzumab in the last 24 months
  • \- Contraindication for MRI or for Gadolinium injection
  • \- Inflammatory diseases of the central nervous system
  • \* not obligatory in 50% of the study population (100 patients)

Outcomes

Primary Outcomes

Not specified

Similar Trials